Cytek Investor Conference Presentation Deck
Safe Harbor Statement
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek's expected revenue for the
full year ended December 31, 2023; Cytek's business and operational goals and strategies; Cytek's business development plans; Cytek's estimated market size and opportunities; Cytek's prospective products;
objectives of management for future operations; and the expected key strategic benefits from the flow cytometry and imaging business acquired from Luminex. Forward-looking statements are neither historical
facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results
of operations, business strategy, and financial needs. All statements other than statements of historical facts contained in this presentation, including, without limitation, statements The words "may," "will,"
"expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" and other similar expressions are intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks relating to
adjustments to the revenue estimate that may be required in connection with the completion of the Company's year-end closing and auditing procedures; global economic and market conditions; Cytek's ability
to evaluate its prospects for future viability and predict future performance; Cytek's ability to accurately forecast customer demand and adoption of its products; Cytek's ability to successfully integrate the
acquired Luminex business and recognize the anticipated benefits of the transaction; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and
potential products; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and retain key employees; Cytek's ability to maintain, protect and
enhance its intellectual property; and Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations. Information on these and additional risks and
uncertainties and other information affecting Cytek's business and operating results is contained in Cytek's Quarterly Report on Form 10-Q for the quarter ended November 14, 2023, and in its other filings with
the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Except as required by applicable law, Cytek does not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made
about the accuracy of any such forward-looking statements.
Certain information contained in this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Cytek's internal estimates and research. While
Cytek believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness
of, any information obtained from third-party sources. While Cytek believes its internal research is reliable, such research has not been verified by any independent source. Cytek's estimates are derived from
publicly available information, management's knowledge of the Cytek's industry and management's assumptions based on such information and knowledge, which they believe to be reasonable. This data
involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors.
This presentation includes certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the twelve months ended September 30, 2023. Management believes that non-GAAP
financial measures, including "Adjusted EBITDA", taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other
expenses that are not indicative of the company's core operating results. Management uses non-GAAP measures to compare the company's performance relative to forecasts and strategic plans and to
benchmark the company's performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an
understanding of the company's operating results as reported under U.S. GAAP. Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and
the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the tables accompanying this
presentation.
Cytek, Full Spectrum Profiling, FSP, Northern Lights, Cytek Aurora, cFluor, Tonbo, Amnis, Guava, Muse, ImageStream, Flow Sight, CellStream and easyCyte are trademarks of Cytek Biosciences, Inc. Other
trademarks appearing in this presentation are the property of their respective holders.
CYTEK
TRANSCEND THE CONVENTIONAL
NView entire presentation